After almost a year in remission, in late March Kris had a routine blood test which indicated an increase in her CA 125 levels. Her recurrence was confirmed with a PET scan. A few weeks ago she started chemo again, this time using Doxil (Doxorubicin). Fortunately, she was accepted in a trial sponsored by NYU Langone of a new cancer drug called a PARP inhibitor. PARP inhibitors appear to improve progression-free survival in women with recurrent platinum-sensitive ovarian cancer (as described by Wikipedia). She starts the PARP inhibitor next week in combination with Doxil. Unfortunately there can be numerous side effects to the new regimen including nausea, vomitting, rashes and heart and liver issues. Because of this she has to get blood tests twice a week to start. During chemo her hands and feet are kept cold with ice. Will keep you posted.
No comments:
Post a Comment